Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
Slika profila

Vlatko Pejša

5214

Vlatko

Pejša

dr. sc.

Naziv Uloga Akcije
Novi klinički pristupi kroničnim mijelo i limfoproliferacijama voditelj
Naziv Akcije
(KroHem) Mitrović, Zdravko ; Dujmović, Dino ; Jakšić, Ozren ; Bašić-Kinda, Sandra ; Gaćina, Petar ; Periša, Vlatka ; Prka, Željko ; Dreta, Barbara ; Galušić Davor ; Holik, Hrvoje et al. Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem) // European journal of haematology, 111 (2023), 13957, 7. doi: 10.1111/ejh.13957
Lucijanić, Marko ; Huzjan Korunić, Renata ; Ivić, Marija ; Fazlić Džankić, Amina ; Jonjić, Željko ; Mitrović, Zdravko ; Prka, Željko ; Piršić, Mario ; Jakšić, Ozren ; Gaćina, Petar et al. Psoas muscle index at the time of diagnosis might reflect the prognosis of classical Hodgkinʼs lymphoma patients // Wiener klinische Wochenschrift, 134 (2022), 1-2; 80-82. doi: 10.1007/s00508-021-01850-x
Sabljić, Anica ; Sedinić Lacko, Martina ; Kušec, Rajko ; Pejša, Vlatko ; Lucijanić, Marko No Evident Prognostic Benefit of Statin Use in Diffuse Large B-Cell Lymphoma Patients with Unfavorable Disease Features Treated with R-DA- EPOCH // Pharmacology, 107 (2022), 11-12; 623-627. doi: 10.1159/000526625
Lucijanić, Marko ; Huzjan Korunić, Renata ; Sedinić, Martina ; Kovačević, Stjepan ; Atić, Armin ; Pejša, Vlatko ; Kušec, Rajko Baseline and progressive adipopenia in newly diagnosed patients with diffuse large B-cell lymphoma with unfavorable features are associated with worse clinical outcomes // Leukemia & lymphoma, 63 (2022), 7; 1556-1565. doi: 10.1080/10428194.2022.2034160
Galušić, Davor ; Bašić-Kinda, Sandra ; Pijuk, Anđela ; Milunović, Vibor ; Dreta, Barbara ; Franjić, Neven ; Coha, Božena ; Sinčić-Petričević, Jasminka ; Gaćina, Petar ; Pejša, Vlatko et al. Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases // HemaSphere, 6 (2022), 12; e807, 6. doi: 10.1097/HS9.0000000000000807
Lucijanić, Marko ; Huzjan Korunić, Renata ; Ivić, Marija ; Fazlić Džankić, Amina ; Kušec, Rajko ; Pejša, Vlatko Perirenal and subcutaneous fat differently affect outcomes in newly diagnosed classical Hodgkin lymphoma patients // Hematological oncology, 39 (2021), 4; 575-579. doi: 10.1002/hon.2887
Bašić-Kinda, Sandra ; Hude, Ida ; Ranković, Ena ; Ostojić-Kolonić, Slobodanka ; Pejša, Vlatko ; Radman, Ivo ; Bogeljić-Patekar, Martina ; Jakšić, Ozren ; Dubravčić, Klara ; Franić-Šimić, Ivana et al. Comparison of different schedules of rituximab and chlorambucil in previously untreated chronic lymphocytic leukemia: a retrospective study of Krohem // Journal of cancer science and clinical therapeutics, 5 (2021), 4; 426-433. doi: 10.26502/jcsct.5079128
Lucijanić, Marko ; Krečak, Ivan ; Galušić, Davor ; Sedinić, Martina ; Holik Hrvoje ; Periša, Vlatka ; Morić Perić, Martina ; Zekanović, Ivan ; Štoos- Veić, Tajana ; Pejša, Vlatko et al. Higher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis // Wiener klinische Wochenschrift, 133 (2021), 3-4; 97-103. doi: 10.1007/s00508-020-01802-x
Lucijanić, Marko ; Huzjan Korunić, Renata ; Sedinić, Martina ; Kušec, Rajko ; Pejša, Vlatko More pronounced muscle loss during immunochemotherapy is associated with worse clinical outcomes in newly diagnosed patients with diffuse large B-cell lymphoma with unfavorable features // Therapeutics and clinical risk management, 17 (2021), 1037-1044. doi: 10.2147/tcrm.s323749
Lucijanić, Marko ; Huzjan Korunić, Renata ; Sedinić, Martina ; Kušec, Rajko ; Pejša, Vlatko Prognostic impact of psoas muscle index in patients with diffuse large B-cell lymphoma might be dependent on the immunochemotherapy type // Leukemia & lymphoma, 62 (2021), 10; 2535-2538. doi: 10.1080/10428194.2021.1919667
nije evidentirano
nije evidentirano